Would you like to know if you are eligible for the Neridronate Treatment? Book your free video call now!

CRPS Treatment: pain in foot and leg for 11 months

General details and patient's info

 

Gender:Male.
Age:10 years old at the time of treatment.
Home Country:United Kingdom.
Illness duration:11 months prior to Neridronate Treatment.
Cause:Right ankle fracture (football injury).
Symptoms:Persistent pain, sensitivity to touch, loss of muscles. Mobility issues, difficulty keeping right foot flat. Difficulty walking, crutches needed for short distances and wheelchair for longer ones. Allodynia and difficulty bearing any weight.
Clinical evaluation:CRPS diagnosis. Inversion injury to the right ankle with ligamentous damage and a small avulsion fracture. Large painful area on the back of right calf. Allodynia, muscle wasting and decreased range of movement. Occasionally changes in temperature and color. Difficult to engage some movements, such as straightening the leg or weight bearing.
Time of treatment:December 2019.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient underwent 6 different treatments before, which brought small results and did not help with recovering his range of motion. He was followed by a pain management doctor who also prescribed medications and supplements.
Since he is a very young sporty boy, his goal was to have 0 pain and be able to go back to his activities and social life. His mother met the mom of another boy treated by MTI for CRPS 4 months before: they just lived one block away! When she realized that this boy was doing much better after the Neridronate infusions, she researched everything about it and decided that it was the best option for her son.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 60 mg given 4 times.
4 Neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330
4 Pantoprazole infusions; Paracetamol; Prednisone.

Daily Report

DAY 1: Arrival at the Venice airport, greeted by his Patient Manager, followed by check-in at her first Hotel in Venice. Briefing focused on next days.

DAY 2: Morning pick-up by his Patient Manager, 1st visit with the Rheumatologist Professor and 1st Neridronate infusion. The patient is happy to be in Italy; he is worried about the needle for the I.V., but the nurse reassures him, and make it easy and comfortable for him.

DAY 3: Morning pick-up by his Patient Manager, 2nd Neridronate infusion. The patient feels well, and he is peaceful.

DAY 4: Morning pick-up by his Patient Manager, 3rd infusion. The patient feels well but he is very tired.

DAY 5: Morning pick-up by his Patient Manager, 2nd visit with the Rheumatologist Professor and last infusion. The boy feels well but is still tired, however he is lively and likes to talk.

DAY 6: Morning pick-up by his Patient Manager and drop off at the Verona airport for the flight back home.

Follow up

FEBRUARY 2020 (2 months after treatment):
the patient showed real improvements, reduced sensitivity, and improvement of mobility. He still uses crutches to walk outside but does not need them anymore at home and he can climb stairs. He can also wear jeans again!

JUNE 2020 (6 months after treatment):
the patient is doing much better, does not feel pain anymore and he is back to several activities. He is starting to play sports again little by little.

FEBRUARY 2023 (3 years after treatment):
as his mother reports, the patient is thriving, in full remission and playing hockey at school and with a Team at very high level.

Conclusion

Children and teenagers can be affected by CRPS too. Even though doctors around the world are often afraid to treat them, they still can undergo, successfully as shows this case, the Neridronate treatment. As per their experience and knowledge, Rheumatologists could lower the Neridronate dosage according to the patient’s age and weight, to pursue the best outcome and keep the possible side effects under control.

The Neridronate treatment allowed the child to reach full and lasting remission. He is now thriving, back to playing sports, and his severe skin sensitivity is solved which allows him to wear clothes without suffering.

DISCLAIMER
This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.